10-Q: Nutra Pharma Reports Q2 Net Income Amidst Going Concern Doubts

Nutra Pharma Corp. reported a net income of $369,577 for Q2 2025, driven by non-operating gains, despite ongoing substantial doubt about its ability to continue as a going concern due to significant accumulated deficits and debt defaults.

Summary

• Net income of $369,577 was reported for the three months ended June 30, 2025, a significant improvement from a net loss of $367,139 in the prior-year period.
• Net sales to unrelated customers increased by 63.47% to $84,532 for Q2 2025 and by 77.22% to $158,506 for the six months ended June 30, 2025.
• Gross profit margin for Q2 2025 was 61.9%, comparable to 62.0% in Q2 2024, but adjusted for reserves, the current quarter's margin (61.9%) was lower than the prior year (78.9%) due to higher manufacturing costs for private label products.
• The accumulated deficit reached $77,266,483 at June 30, 2025, with a working capital deficit of $15,888,753 and a stockholders deficit of $15,833,260.
• Substantial doubt exists regarding the company's ability to continue as a going concern, requiring additional financing.
• Total liabilities increased to $16,692,328 at June 30, 2025, from $15,407,409 at December 31, 2024, with a significant amount of indebtedness in default.
• The cash balance increased to $79,069 at June 30, 2025, from $36,447 at December 31, 2024.
• The company settled a lawsuit with CSA 8411, LLC for $125,000, resulting in a gain of $53,526.
• A final judgment in the SEC lawsuit ordered the company to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty, totaling $680,235.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as highly concerning due to the explicit "going concern" warning, substantial accumulated deficit, and significant debt defaults, which overshadow the modest revenue growth and a quarterly net income largely driven by non-operational factors.

Positives

• Net income of $369,577 for the three months ended June 30, 2025, compared to a net loss of $367,139 in the prior-year period.
• Net sales to unrelated customers increased by 63.47% to $84,532 for Q2 2025 and by 77.22% to $158,506 for the six months ended June 30, 2025.
• Gross profit increased to $75,628 for Q2 2025 from $54,845 for Q2 2024.
• A gain of $704,622 was recognized from the change in fair value of convertible notes and derivatives for Q2 2025.
• A gain of $53,526 was recognized on the settlement of debt and accrued expenses in Q2 2025.
• The cash balance increased to $79,069 at June 30, 2025, from $36,447 at December 31, 2024.
• RPI78M was granted Orphan Status by the FDA for pediatric Multiple Sclerosis in September 2015, which offers benefits like shorter approval timelines and fee waivers.

Negatives

• Substantial doubt exists about the ability to continue as a going concern due to recurring significant losses, an accumulated deficit of $77,266,483, a working capital deficit of $15,888,753, and a stockholders deficit of $15,833,260 at June 30, 2025.
• Net loss for the six months ended June 30, 2025, increased to $1,035,346 from $794,073 in the prior-year period.
• Cash used in operating activities increased significantly to $693,376 for the six months ended June 30, 2025, from $264,822 in the prior-year period.
• Selling, general and administrative expenses increased by 33.5% to $366,157 for Q2 2025 and by 29.67% to $784,307 for the six months ended June 30, 2025.
• Gross margin, excluding inventory reserves, decreased to 61.9% for Q2 2025 from 78.9% in Q2 2024, primarily due to higher manufacturing costs for private label products.
• A loss of $302,687 was recognized from the change in fair value of convertible notes and derivatives for the six months ended June 30, 2025, worsening from a $122,990 loss in the prior-year period.
• Disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in internal control over financial reporting.
• The company's common stock is on the OTC Market Groups Expert Market, which limits its ability to raise capital.
• A final judgment in the SEC lawsuit ordered the company to pay $680,235 in disgorgement, prejudgment interest, and civil penalties.

Risks

• Ability to continue as a going concern is contingent on securing additional financing, increasing ownership equity, and attaining profitable operations.
• Inability to raise sufficient equity capital or secure additional loans from officers and directors.
• Intense competition in the biotechnology area.
• Failure to successfully execute planned partnering and out-licensing of products or technologies.
• Adverse effects from economic downturns and credit market crises on financing and operations.
• Substantial and rising biotechnology industry-related litigation.
• Increased costs, penalties, and business losses from failure to comply with healthcare industry legal/regulatory requirements.
• Material weaknesses in internal control over financial reporting.
• The company's common stock being on the OTC Market Groups Expert Market limits capital raising.
• Many convertible notes are in default, leading to potential legal actions or unfavorable settlement terms.
• Potential for a $400,000 consent judgment if payments are defaulted on the CSA 8411, LLC settlement.
• Reliance on related party transactions that may not be at arms-length.
• Uncertainty regarding the timing and success of human clinical studies for drug candidates due to lack of funding.
• Full reserves were necessary for supplier advances for venom, indicating potential issues with inventory or suppliers.

Future Outlook

The company plans to expand production capacity, re-engage in Canadian regulatory approval for Nyloxin in 2026, and initiate Phase I/II trials for RPI78M in pediatric Multiple Sclerosis in 2026, contingent on securing adequate financing. It estimates requiring approximately $1,200,000 to fund existing operations over the next twelve months and will need additional capital to manufacture products and reduce debt.

Management Comments

• "Our business during the six months ended June 30, 2025 has focused upon marketing our homeopathic drugs for the treatment of pain."
• "We are currently expanding production capacity in our facility to allow spot production of our products and private label brands."
• "Our goal is that with Nyloxin, we can greatly reduce the instances of opiate abuse and overuse of NSAIDS in high risk groups like the US military."
• "We have continued to work with our consultants to understand why our products were improperly removed the Federal Supply Schedule and when we may be able to get re-listed."
• "Due to lack of funding and then the subsequent COVID crisis, we have waited to complete the approval process to begin distributing Nyloxin and expect to re-engage in the process in 2026."
• "We cannot provide any timeline for these studies until adequate financing is available."
• "Our goal is to initiate these trials [for RPI78M] in 2026."
• "As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern."
• "The Company will require additional capital to manufacture Nyloxin and Pet PainAway and to reduce our debt level."
• "We estimate that we will require approximately $1,200,000 to fund our existing operations over the next twelve months."
• "There can be no assurance that we will be able to raise sufficient equity capital to fund our working capital requirements on terms acceptable to us, or at all."
• "We may also seek additional loans from our officers and directors; however, there can be no assurance that we will be successful in securing such additional loans."

Industry Context

StockSavvy.ai notes that the biotechnology and pharmaceutical industry is highly competitive and capital-intensive, particularly for drug discovery and clinical trials. Nutra Pharma's focus on homeopathic pain relievers and a drug pipeline for serious conditions like HIV and MS places it in diverse, yet challenging, market segments. The FDA Orphan Status for RPI78M is a significant advantage, potentially accelerating development and reducing costs, which is crucial for a company with limited funding. However, the reliance on non-opioid pain relief aligns with broader healthcare trends seeking alternatives to addictive medications. The company's financial struggles and inability to secure consistent funding for R&D and regulatory approvals put it at a significant disadvantage compared to larger, well-capitalized competitors in both the OTC and biologics markets.

Comparison to Industry Standards

• StockSavvy.ai notes that the company's accumulated deficit of over $77 million and ongoing going concern warning are significantly below industry standards for a stable, publicly traded biotechnology company.
• The reliance on related party transactions and the OTC Expert Market for capital raising are not typical for companies pursuing advanced drug development, which usually attract institutional investment or operate on major exchanges.
• The FDA Orphan Status for RPI78M for pediatric Multiple Sclerosis is a positive regulatory achievement, comparable to similar designations received by companies like Biogen (for Spinraza in SMA) or Sarepta Therapeutics (for Exondys 51 in Duchenne muscular dystrophy), which can streamline development and offer market exclusivity. However, without adequate funding, the company's ability to capitalize on this status is severely hampered.
• The company's gross profit margin of 61.9% for Q2 2025, while decent, is impacted by higher manufacturing costs for private label products, suggesting potential inefficiencies or unfavorable contract terms compared to established pharmaceutical manufacturers.

Management Changes

Corporate Governance

Legal Proceedings

• CSA 8411, LLC v. Nutra Pharma Corp.: Lawsuit filed October 12, 2018, to recover $100,000. Settled on May 19, 2025, for $125,000, payable in installments. A gain of $53,526 was recognized. Default on payments could lead to a $400,000 consent judgment.
• Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus: Lawsuit filed September 28, 2018, alleging fraud and securities law violations. Final judgment issued July 2024, ordering the company to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty, totaling $680,235.
• Marc Weller v. Nutra Pharma Corporation: Settled in January 2026 (subsequent event) for $20,000 cash and 60,000,000 common shares, cancelling approximately $175,000 in outstanding notes.

Related Party Transactions

• Sales to Avini Health (owned by former CEO Rik Deitsch) accounted for 31% of total revenues in Q2 2025 and 32% for H1 2025.
• Avini Health forgave $240,557 in deferred revenue in 2024, recorded as a capital contribution.
• Company uses Avini's leased facility rent-free and shares space/resources, with Avini paying all lease and office-related expenses.
• Raw materials purchased from Avini Health totaled $14,000 in Q2 2025 and $27,000 in H1 2025.
• $5,000 received from Avini Health for shared use of equipment in Q2 2025.
• Due to Rik Deitsch (former CEO) and his controlled companies: $1,131,833 at June 30, 2025.
• Accrued payroll due to officers: $1,740,845 at June 30, 2025.
• Accrued interest to a director: $191,096 at June 30, 2025.
• Convertible notes payable totaling $253,000 reclassified to "due to officers" in March 2024.
• All related party transactions were not conducted on an arms-length basis.

Stakeholder Impact

• Shareholders: Face substantial dilution risk from potential future equity raises and conversion of existing convertible debt. The "going concern" warning indicates a high risk of investment loss. The stock being on the OTC Expert Market limits liquidity and visibility.
• Creditors: Many notes are in default, indicating high credit risk and potential for prolonged negotiations or legal action.
• Employees: The company's precarious financial position and reliance on external funding could impact job security and operational stability.
• Customers: Potential for disruption in product availability or quality if financial instability affects manufacturing or supply chains.
• Suppliers: Risk of delayed or non-payment due to the company's liquidity issues and significant liabilities.

Next Steps

• Expand production capacity in the facility for spot production of products and private label brands.
• Re-engage in the Canadian regulatory approval process for Nyloxin in 2026.
• Complete human clinical studies comparing Nyloxin Extra Strength to prescription pain relievers, contingent on adequate financing.
• Initiate Phase I/II trials for RPI78M in the treatment of Pediatric Multiple Sclerosis in 2026.
• Secure additional financing to fund operations and reduce debt, with an estimated need of $1,200,000 for the next twelve months.
• Continue negotiations for settlement of various defaulted promissory and convertible notes.
• Make remaining installment payments for the CSA 8411, LLC settlement through February 2026.
• Make installment payments for the Marc Weller settlement through April 2026.
• Amortize debt discounts and issuance-related costs for newly issued convertible promissory notes and future receipts agreements.
• Evaluate the impact of adopting ASU No. 2024-04 and ASU No. 2025-05, effective January 1, 2026.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by an explicit "going concern" warning, a massive accumulated deficit, and significant debt defaults. While Q2 2025 showed a net income, it was primarily driven by non-operating gains from derivative fair value changes and debt settlements, not sustainable operational profitability. The company's inability to fund operations from sales, reliance on the OTC Expert Market for capital, and material weaknesses in internal controls present an exceptionally high risk profile. The SEC penalties further underscore governance issues. A seasoned investor would view these factors as overwhelming negatives, indicating a high probability of further value erosion and potential bankruptcy.

Keywords

Nutra Pharma Corp, NPHC, biotechnology, pain relief, homeopathic drugs, Nyloxin, Pet PainAway, Luxury Feet, Equine Pain-Away, Cell Defender, drug discovery, RPIMN, RPI78M, Multiple Sclerosis, HIV, Orphan Status, SEC filing, 10-Q, financial results, going concern, debt default, convertible notes, related party transactions, litigation, capital raise, OTC Expert Market